HealthDay News — An investigational serogroup B meningococcal vaccine seems to have protected vaccinated individuals from the disease during an outbreak, according to a study published in Pediatrics.
Noting that the FDA authorized use of an investigational serogroup B meningococcal (MenB) vaccine to control an outbreak of serogroup B meningococcal disease in 2013 to 2014 in a university in New Jersey, Lucy A. McNamara, PhD, of the CDC in Atlanta, and colleagues investigated the outbreak and response. Vaccination coverage data were collected during the vaccination campaign.
Nine cases of serogroup B meningococcal disease were identified between March 25, 2013, and March 10, 2014. For all eight isolates available, laboratory typing results were identical. In the target population, 89.1% coverage with the two-dose vaccination series was obtained through May 14, 2014.
There were no additional cases of serogroup B meningococcal disease in students at the university from the initiation of MenB vaccination through Feb. 1, 2015. The ninth case occurred in an unvaccinated close contact of students from the university in March 2014.
“The outbreak investigation and highly successful vaccination campaign described here can serve as a model for how to approach similar outbreaks in the future,” concluded the investigators.